Morepen Laboratories Limited , a prominent pharmaceutical company, conducted its 40th Annual General Meeting (AGM) on September 6, 2025, via video conferencing. The meeting, chaired by Sushil Suri, Chairman and Managing Director, addressed several crucial agenda items and passed important resolutions.

Key Highlights

• Dividend Declaration: The company approved a final dividend of ₹0.20 per equity share with a face value of ₹2 each for the financial year ended March 31, 2025.

• Financial Statements: Shareholders adopted the audited financial statements, including consolidated financial statements, for the year ended March 31, 2025.

• Director Reappointment: Sanjay Suri was reappointed as a director, retiring by rotation and offering himself for reappointment.

Special Business Items

Independent Director Reappointment

Dr. Savita was reappointed as an Independent Director.

Whole-Time Director Reappointment

Sanjay Suri was reappointed as a Whole-Time Director.

Medical Devices Business Transfer

The meeting approved an extension of time for transferring the Medical Devices Business to the subsidiary, Morepen Medipath Limited, as a going concern on a slump sale basis.

Auditor Appointments

• M/s. Vijender Sharma & Co. were ratified as Cost Auditors.
• M/s. PD and Associates were appointed as Secretarial Auditors for a term of five years.

Related Party Transactions

The AGM approved salary arrangements for relatives of key management personnel:

• Ms. Aanandi Suri, relative of Whole-Time Director Sanjay Suri
• Mr. Arjun Suri, relative of Chairman & Managing Director Sushil Suri

Financial Flexibility

A special resolution was passed allowing for the conversion of loans into shares or convertible instruments of the company.

Meeting Proceedings

The AGM, which began at 1:00 p.m. IST, was conducted in compliance with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. Shareholders were provided with remote e-voting facilities from September 3 to September 5, 2025, and additional e-voting during the meeting.

Mr. Praveen Dua of M/s. PD and Associates was appointed as the scrutinizer to oversee the voting process. The meeting concluded at 2:19 p.m. IST, with the company set to announce the voting results separately.

This AGM marked a significant event for Morepen Laboratories, addressing key governance issues and setting the stage for the company's future strategic direction in the pharmaceutical sector.

Morepen Laboratories Limited , a prominent player in the pharmaceutical sector, has announced a strategic move into the medical devices industry with the incorporation of a new step-down subsidiary, Sigmacheck Health Private Limited. The Ministry of Corporate Affairs approved the incorporation on August 13, 2025, marking a significant expansion for the company.

Key Details of the New Subsidiary

Strategic Rationale

The formation of Sigmacheck Health Private Limited aims to cater to the growing demands in the medical devices sector. This move aligns with Morepen Laboratories' strategy to diversify its portfolio and tap into the expanding healthcare equipment market.

Financial Aspects

Morepen Medipath Limited, the direct parent company, has subscribed to all 10,000 equity shares for a total consideration of ₹1,00,000, paid in cash. This investment underscores Morepen Laboratories' commitment to establishing a strong foothold in the medical devices industry.

Market Implications

The entry into the medical devices industry could potentially enhance Morepen Laboratories' market position and diversify its revenue sources. As the healthcare sector continues to evolve, the demand for innovative medical devices is likely to grow.

Looking Ahead

As Sigmacheck Health Private Limited begins its operations, investors and industry observers will be keen to see how this new venture contributes to Morepen Laboratories' overall growth strategy and financial performance in the coming years.

Morepen Laboratories continues to demonstrate its commitment to growth and innovation in the healthcare sector with this strategic move into the medical devices industry.